Weill Cornell Medical College Revenue and Competitors

Location

N/A

Total Funding

Industry

Estimated Revenue & Valuation

  • Weill Cornell Medical College's estimated annual revenue is currently $75M per year.(i)
  • Weill Cornell Medical College's estimated revenue per employee is $539,568

Employee Data

  • Weill Cornell Medical College has 139 Employees.(i)
  • Weill Cornell Medical College grew their employee count by 72% last year.

Weill Cornell Medical College's People

NameTitleEmail/Phone
1
Chief Information OfficerReveal Email/Phone
2
SVP & Chief Operating Officer, (NYP Westchester)Reveal Email/Phone
3
Senior Technology Officer (Weill Cornell Medicine)Reveal Email/Phone
4
Associate Director, Advanced Technology Integration ServicesReveal Email/Phone
5
Director & Associate Director, Core Informatics & Group Biomedical InformaticsReveal Email/Phone
6
Director, Talent Acquisition & OnboardingReveal Email/Phone
7
Dean, Weill Cornell Graduate School Medical SciencesReveal Email/Phone
8
Chair, Department Pathology and Laboratory MedicineReveal Email/Phone
9
Associate Dean (Faculty Development)Reveal Email/Phone
10
Vice Provost, External AffairsReveal Email/Phone

What Is Weill Cornell Medical College?

Weill Cornell Medical College offers state-of-the-art diagnosis and treatment of tumors affecting the skull base. The skull base is the area located at the floor of the cranial cavity. Because of the complexity of this area, skull base surgery is one of the most challenging procedures for a neurosurgeon to perform. The skull base surgery program at Weill Cornell Medical College crosses many disciplines, including those of the skull, head and neck, and brain. We have a multi-disciplinary team of specialists that works together to develop comprehensive treatment plans for patients with skull base tumors and other disorders. The College's team of specialists includes neuro-oncologists, radiation oncologists, neuro-otologists, neurosurgeons, neurologists, ophthalmologists, head and neck surgeons and psychologists. Neurosurgeons at Weill Cornell Medical College diagnose and treat skull base disorders using advanced 3-D imaging equipment, which provides extremely clear pictures of tumors. This allows for safer and more complete resections of tumors and resolutions of other disorders, and thus improved outcomes for patients. With the most advanced technology in radiosurgery and comprehensive services in radiation oncology, we provide the best care for a broad range of tumors in the ear and base of the skull. We have extensive experience in gamma knife radiosurgery, which is a safe, non-invasive, high precision device that treats many types of lesions, including deep-seated brain tumors and AVMs (arteriovenous malformations). In addition, our team of medical professionals has created and designed many treatment paradigms now being used routinely around the world. With access to intraoperative magnetic resonance imaging (MRI) and stealth image guidance, our surgeons perform minimally invasive procedures that ensure complete excision of tumors. Weill Cornell Medical College participates in ongoing clinical trials to advance treatment for skull base tumors. Our multidisciplinary team also continues to create innovations that will contribute to new treatment paradigms for complex skull base tumors.

keywords:N/A

N/A

Total Funding

139

Number of Employees

$75M

Revenue (est)

72%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Weill Cornell Medical College News

2022-04-20 - Hospital for Special Surgery (HSS) Opens Major Expansion on Long ...

An affiliate of Weill Cornell Medical College, HSS has a main campus in New York City and facilities in New Jersey, Connecticut and in the...

2022-03-22 - A Celebratory Match Day at Weill Cornell Medicine

Oh and her fellow classmates in the Weill Cornell Medical College Class of 2022 learned on national Match Day where they will be doing their...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$24.3M13936%N/A
#2
$25M139-3%N/A
#3
$35.3M1395%N/A
#4
$40M139-7%$37.4M
#5
$31.6M13910%$48.6M